Biopharmaceutical company Cytokinetics is focusing on muscle activators and inhibitors as potential treatments for cardiovascular diseases. CEO Robert Blum has said that while there have been advances in cardiovascular medicine, very few relate directly to cardiac muscle. Their drugs are designed to modulate the proteins involved in cardiac muscle bio-machinery. The company has reported positive results from a pivotal phase 3 trial of their heart drug aficamten in treating obstructive hypertrophic cardiomyopathy, aiming for availability to patients in 2025.
Cedars-Sinai CIO’s tips to ensure genAI is fair, appropriate, valid, effective and safe
Cedars-Sinai’s CIO, Craig Kwiatkowski and his team have developed an AI-powered virtual primary care app, Cedars-Sinai Connect. The app has increased primary care capacity by
